We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Daily Bulletin
    • Drug Industry Daily
  • Device News
    • Trending
    • Commercial Operations
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Daily Bulletin
    • FDAnews Device Daily Bulletin Premium
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • eCFR and Guidances
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Green Lights Third Indication for Lilly’s Cancer Drug Cyramza

FDA Green Lights Third Indication for Lilly’s Cancer Drug Cyramza

December 22, 2014

The FDA has approved Eli Lilly’s Cyramza to treat the most common type of lung cancer, the latest effort by the drugmaker to vastly increase uses of the oncology drug.

The approval indicates Cyramza (ramucirumab) combined with chemotherapy docetaxel for treating metastatic non-small cell lung cancer in patients whose tumor has progressed during or after treatment with platinum-based chemotherapy.

This is the third indication for Cyramza, which won approval in April as a single agent to treat patients with advanced stomach cancer or gastroesophageal junction (GEJ) adenocarcinoma, a cancer that affects the region where the stomach and esophagus meet. Last month, the FDA approved Cyramza’s use in GEJ patients alongside the chemotherapy drug paclitaxel.

The latest indication was cleared through the agency’s priority review program and supported by a clinical trial of 1,253 participants with previously treated and progressive lung cancer.

Lilly plans to submit more indications for Cyramza. In the first half of 2015 it expects to submit an FDA application for Cyramza in combination with chemotherapy to treat metastatic colorectal cancer, according to the drugmaker’s latest financial report.

The drugmaker also tried to expand the indication to treat breast cancer, but the drug failed in a Phase III trial last year.

The push for new indications for Cyramza comes as the company continues to grapple with the loss of market exclusivity for blockbuster anxiety drug Cymbalta (duloxetine HCl) last December and osteoporosis treatment Evista (raloxifene) in March. — Robert King

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.

Drugs Commercial Operations

Upcoming Events

  • 04Apr

    Optimizing Quality Control Operations with Unified Quality

  • 20Apr

    Medical Device Enforcement: Latest Developments from the FDA, DOJ and FTC

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Wesper Next-Generation Device Cleared for Sleep Test Data Collection

  • FDA Approves First-Ever Treatment for Activated Phosphoinositide 3-Kinase Delta Syndrome

  • FemDx Medsystems Falloposcope Cleared

  • Cyclerion’s Mitochondrial Diseases Candidate Gets Orphan Drug Nod

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing